Skip to main content
Top
Published in: Medical Oncology 1/2009

01-03-2009 | Original Paper

Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin’s lymphoma in a patient with pituitary acromegaly

Authors: A. Taslipinar, E. Bolu, L. Kebapcilar, M. Sahin, G. Uckaya, M. Kutlu

Published in: Medical Oncology | Issue 1/2009

Login to get access

Abstract

The effects of growth hormone are mediated in part by stimulating the production of insulin-like growth factor-1. Insulin-like growth factor-1 has significant effects on cell proliferation and differentiation, it is a potent mitogen, and it is a powerful inhibitor of programmed cell death (apoptosis). Insulin-like growth factor-1 also has a well-established role in the transformation of normal cells to malignant cells. Case reports on a possible association between elevated growth hormone and cancer risk in a variety of patient groups have been published. Here, we describe clinical and laboratory findings for a patient with acromegaly who first developed thyroid cancer, and then, in the follow up period, probably due to poorly controlled insulin-like growth factor-1 levels, developed a large cell non-Hodgkin’s lymphoma. A search revealed that a case with these peculiarities had not previously been reported.
Literature
3.
go back to reference Prisco M, Romano G, Peruzzi F, Valentinis P, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res. 1999;31:80–9.PubMedCrossRef Prisco M, Romano G, Peruzzi F, Valentinis P, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res. 1999;31:80–9.PubMedCrossRef
5.
go back to reference Alves RH, Vaisman M, Brasil RR, Gadelha MR. Acromegaly and non-Hodgkin’s lymphoma. Endocr Pract. 1998;4:279–81.PubMed Alves RH, Vaisman M, Brasil RR, Gadelha MR. Acromegaly and non-Hodgkin’s lymphoma. Endocr Pract. 1998;4:279–81.PubMed
6.
go back to reference Busygina V, Bale AE. Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis. Yale J Biol Med. 2006;79:105–14.PubMed Busygina V, Bale AE. Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis. Yale J Biol Med. 2006;79:105–14.PubMed
9.
go back to reference AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004;10:213–25. AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004;10:213–25.
10.
go back to reference Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab. 1991;72:245–9.PubMed Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab. 1991;72:245–9.PubMed
12.
go back to reference Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39:1–16.PubMed Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39:1–16.PubMed
13.
go back to reference Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327–35.PubMed Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327–35.PubMed
14.
go back to reference Etxabe J, Gaztambide P, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993;16:181–7.PubMed Etxabe J, Gaztambide P, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993;16:181–7.PubMed
17.
go back to reference Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730–4. doi:10.1210/jc.83.8.2730.PubMedCrossRef Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730–4. doi:10.​1210/​jc.​83.​8.​2730.PubMedCrossRef
21.
go back to reference Kasagi K, et al. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid. 1999;9:791–6.PubMedCrossRef Kasagi K, et al. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid. 1999;9:791–6.PubMedCrossRef
22.
go back to reference Cannavò S, et al. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Horm Metab Res. 2000;32:190–5.PubMedCrossRef Cannavò S, et al. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Horm Metab Res. 2000;32:190–5.PubMedCrossRef
23.
go back to reference Gasperi M, et al. Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25:240–5.PubMed Gasperi M, et al. Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25:240–5.PubMed
25.
go back to reference Cats A, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;56:523–6.PubMed Cats A, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;56:523–6.PubMed
28.
go back to reference Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988;66:1158–65.PubMedCrossRef Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988;66:1158–65.PubMedCrossRef
29.
go back to reference Minuto F, et al. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab. 1989;68:621–6.PubMed Minuto F, et al. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab. 1989;68:621–6.PubMed
31.
go back to reference Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569–74. doi:10.1530/eje.1.01888.PubMedCrossRef Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569–74. doi:10.​1530/​eje.​1.​01888.PubMedCrossRef
33.
go back to reference Colao A, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest. 2007;30:693–9.PubMed Colao A, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest. 2007;30:693–9.PubMed
37.
Metadata
Title
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin’s lymphoma in a patient with pituitary acromegaly
Authors
A. Taslipinar
E. Bolu
L. Kebapcilar
M. Sahin
G. Uckaya
M. Kutlu
Publication date
01-03-2009
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 1/2009
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9084-9

Other articles of this Issue 1/2009

Medical Oncology 1/2009 Go to the issue